CN109419794B - Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor - Google Patents
Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor Download PDFInfo
- Publication number
- CN109419794B CN109419794B CN201710780590.8A CN201710780590A CN109419794B CN 109419794 B CN109419794 B CN 109419794B CN 201710780590 A CN201710780590 A CN 201710780590A CN 109419794 B CN109419794 B CN 109419794B
- Authority
- CN
- China
- Prior art keywords
- sprc
- cell
- cysteine
- propargyl
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Abstract
The invention belongs to the field of pharmacy, and relates to application of propargyl cysteine (SPRC, S-propargyl-cysteine) in preparing a medicine for treating tumors in a blood system. The invention detects the influence of SPRC treatment on the cell viability of cancer cells through in vitro T lymphocyte and lymphoma cell culture experiments, and the results show that the SPRC can reduce the cell survival rate, promote cell apoptosis and inhibit S-phase block of cell cycle; can improve the cell activity of apoptosis promoting protein caspase3, and the experimental result shows that the propargyl cysteine has an inhibiting effect on T lymphocyte and lymphoma cell, and the SPRC can be prepared into a therapeutic drug for treating blood system tumor.
Description
Technical Field
The invention belongs to the field of pharmacy, relates to a novel application of propargyl cysteine (SPRC) in preparation of a medicine, and particularly relates to an application of propargyl cysteine (SPRC) in preparation of a medicine for treating tumors in a hematopathy system.
Background
The prior art discloses that allyl cysteine (SAC, S-allyl cysteine) is a natural organic sulfur compound in garlic, is a main effective component in mature garlic extract (Aged garlic extract), and is obtained by degrading S-alk (en) yl cysteine sulfoxides (ACSs). The compounds have been reported in the literature to have anti-tumor, anti-bacterial and anti-fungal properties.
It has been reported that propargyl cysteine (SPRC, S-propargyl-cysteine) has a similar structure to SAC (S-alanine), and has the same cysteine structure. The protection of SPRC against hypoxic injury of myocardial cells and its role in the treatment of digestive system tumors and in combating breast cancer have been reported, but to date, no report has been made on propargyl cysteine (SPRC) against hematological tumors.
Based on the current situation of the prior art, the inventor of the application intends to provide a new pharmaceutical use of propargyl cysteine (SPRC), and particularly relates to a use of propargyl cysteine (SPRC) in preparing a drug for treating hematopathy system tumors.
Disclosure of Invention
The invention aims to provide a new application of propargyl cysteine (SPRC, S-propargyl-cysteine) in pharmacy, and particularly relates to an application of propargyl cysteine (SPRC) in preparing a medicine for treating hematopathy system tumor.
In the present invention, the hematological tumors are especially T lymphocyte leukemia and lymphoma.
The molecular formula and the structure of the propargyl cysteine (SPRC) are shown as the following formula:
in the present invention, the propargyl cysteine (SPRC) can be synthesized by the following synthetic route:
l-cysteine hydrochloride was dissolved in a pre-cooled NH4OH (2M, 240ml) solution, 3-bromopropyne (14.5g, 0.124mol) was added and stirred thoroughly, the mixture was stirred at 0 ℃ for 2h and filtered, and the filtrate was concentrated to a smaller volume by reduced pressure distillation (< 40 ℃) and filtered. Repeatedly washing precipitated solid with ethanol, vacuum evaporating, recrystallizing with water/ethanol at volume ratio of 2: 3 to obtain white needle crystal, and determining by hydrogen spectrum structure detected by nuclear magnetic resonance.
The invention carries out an in-vitro experiment of SPRC for inhibiting tumor cells in a blood system, and detects and compares the influence of SPRC on the cell viability of T lymphocyte leukemia (Jurkat) and lymphoma cells (Raji).
The invention cultures T lymphocyte (Jurkat) and lymphoma cell (Raji) in vitro, and uses SPRC to process, the result shows that SPRC can reduce cell activity of T lymphocyte and lymphoma cell, promote apoptosis of T lymphocyte and lymphoma cell, and inhibit cell cycle of T lymphocyte and lymphoma cell, the result shows that SPRC can be used as therapeutic drug for treating T lymphocyte and lymphoma cell.
The invention obviously promotes the cell activity of caspase3 which promotes apoptosis in T lymphocytes and lymphoma cells by detecting SPRC. The results further confirm that SPRC has an inhibitory effect on T lymphocytes and lymphoma cells, and can be prepared into therapeutic drugs for the treatment of T lymphocytes and lymphoma cells.
For the purpose of facilitating understanding, the invention will be described in detail below with reference to specific drawings and examples. It is specifically noted that the specific examples and figures are for illustrative purposes only and it will be apparent to those skilled in the art that, in light of the description herein, various modifications and changes can be made in the invention which are within the scope of the invention.
Drawings
FIG. 1 is a CCK-8 method for detecting cell viability, showing the effect of SPRC on cell viability of T lymphocytes (Jurkat) and lymphoma cells (Raji); wherein, Control is a normal Control group, and the drug-treated groups were 3 concentrations (mg/ml) of 0.16,0.8 and 1.6mg/ml of SPRC, respectively, and represents that p is less than 0.05 compared with the normal group.
FIG. 2 is a graph showing the apoptosis observed by Annexin I and PI staining, showing the effect of SPRC on apoptosis of T lymphocytes (Jurkat) and lymphoma cells (Raji);
FIG. 3 is a graph of the inhibitory effect of SPRC on the cell cycle of T lymphocytes (Jurkat) and lymphoma cells (Raji) showing the effect of SPRC on the cell cycle of T lymphocytes (Jurkat) and lymphoma cells (Raji);
wherein, labeled in fig. 2 and 3, J1 is a normal group of T lymphocytes, J2 is a group of T lymphocytes (Jurkat) treated with 0.8mg/ml of SPRC, J3 is a group of T lymphocytes (Jurkat) treated with 1.6mg/ml of SPRC, R1 is a normal control group of lymphoma cells (Raji), R2 is 0.8mg/ml of SPRC-treated lymphoma cells (Raji), and R3 is 1.6mg/ml of SPRC-treated lymphoma cells (Raji) — indicating that p < 0.05 as compared with the normal group.
FIG. 4 is a graph of SPRC-promoted caspase3 activity, where Control is the normal Control group, SPRC 0.8mg/ml, and SPRC 1.6mg/ml are the 2 concentration treatment groups of SPRC, respectively; denotes p < 0.05 compared to normal group; indicates p < 0.01 compared to normal group.
Detailed Description
Example 1 cell lines and culture mode
Human T lymphocytes (Jurkat) and lymphoma cells (Raji) cells (purchased from shanghai life science research institute of china cell bank). The culture conditions are as follows: jurkat and Raji cells were cultured in RPMI 1640 containing 10% fetal bovine serum and 1-2% streptomycin (100U/ml), respectively, and the cells were cultured in a 5% CO2 incubator at 37 ℃.
Example 2 SPRC cell viability reducing experiment
The cells were seeded in 96-well plates at 5 × 10-3 Jurkat and Raji cells per well, 200ul per well volume. SPRC was added to final concentrations of 0.16mg/ml,0.8mg/ml, 1.6mg/ml and 3.2mg/ml, respectively. After 48 hours of treatment, the CCK-8 method detects the cell viability, and the results are shown in figure 1, the cell viability of the SPRC treatment groups with the concentrations of 0.16mg/ml,0.8mg/ml, 1.6mg/ml and 3.2mg/ml is obviously lower than that of the normal control group, and the SPRC can inhibit the cell viability of T lymphocytes and lymphoma cells.
Example 3 SPRC-facilitated apoptosis assay
Jurkat and Raji cells were seeded in culture dishes and treated with 0.8 and 1.6mg/ml SPRC for 48 hours. The detection results of the flow cytometry after cells are stained with Annexin I and PI are shown in FIG. 2, the detection results of the flow cytometry show that 0.8mg/ml of SPRC can induce apoptosis of the cells, and 1.6mg/ml of SPRC significantly induces apoptosis of the cells.
Example 4 SPRC inhibition of cell cycle experiments
Jurkat and Raji cells were seeded in culture dishes and treated with 0.8 and 1.6mg/ml SPRC for 48 hours. The detection result of the PI stained cells by the flow cytometer is shown in figure 3, the detection result of the flow cytometer shows that 0.8mg/ml of SPRC has a blocking effect on the cell cycle, wherein 1.6mg/ml of SPRC significantly induces the cell cycle to be blocked in the S phase.
Example 5 SPRC improves caspase3 cell viability
Collecting Jurkat treated by SPRC for 48 hours and total protein of Raji cells, and detecting the activity of caspase3 in the cells by using an enzyme activity method; the results show that: the SPRC can obviously promote the cell activity of caspase 3.
Claims (1)
1. The application of propargyl cysteine in preparing a medicament for treating tumors in a blood system, wherein the structure of the propargyl cysteine is shown as the following formula:
the propargyl cysteine exerts its effect in S phase by arresting the leukemic cell cycle; the hematological tumors are T lymphocyte leukemia and lymphoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710780590.8A CN109419794B (en) | 2017-09-01 | 2017-09-01 | Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710780590.8A CN109419794B (en) | 2017-09-01 | 2017-09-01 | Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109419794A CN109419794A (en) | 2019-03-05 |
| CN109419794B true CN109419794B (en) | 2021-05-04 |
Family
ID=65512997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710780590.8A Active CN109419794B (en) | 2017-09-01 | 2017-09-01 | Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109419794B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309474A (en) * | 2010-07-02 | 2012-01-11 | 复旦大学 | Application of S-propargyl-cysteine to preparation of medicament for treating digestive system tumors |
-
2017
- 2017-09-01 CN CN201710780590.8A patent/CN109419794B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309474A (en) * | 2010-07-02 | 2012-01-11 | 复旦大学 | Application of S-propargyl-cysteine to preparation of medicament for treating digestive system tumors |
Non-Patent Citations (1)
| Title |
|---|
| H2S Donor, S-Propargyl-Cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S?;Kaium MA等;《PLoS ONE》;20110627;第6卷(第6期);e20525. doi:10.1371/journal.pone.0020525，特别是摘要，第4页右栏 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109419794A (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA031325B1 (en) | Cyclic peptidomimetic compounds as immunomodulators | |
| EP4005591A1 (en) | Anti-neoplastic combined pharmaceutical composition and application thereof | |
| EP3682894B1 (en) | Cell autophagy inhibitor and preparation method therefor and application thereof | |
| CA2988989A1 (en) | Composition containing carboplatin and use | |
| CN109419794B (en) | Application of propargyl cysteine in preparing medicine for treating hematopathy system tumor | |
| CN113274485A (en) | Application of scorpion venom polypeptide Smp24 in preparation of antitumor drugs | |
| CN107865886B (en) | Application of ginseng polysaccharide in preparing medicine for protecting vascular endothelial cells | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN102784134A (en) | Application of aromatic acid derivative with nitric oxide donor in preparation of medicines for treating malignant cancers | |
| CN103992394B (en) | The cationic peptide of a kind of Prof. Du Yucang and the purposes in preparing antineoplastic thereof | |
| CN105663147B (en) | Application of 4-hydroxy salicylanilide in preparation of antitumor drugs | |
| CN110075269B (en) | Application of Murabutide in preparation of medicine for preventing and treating bone marrow, small intestine and spleen injuries caused by ionizing radiation | |
| CN103585211B (en) | The application of Dorema ammoniacum resin extract in preparation treatment leukemia medicament | |
| CN111407766A (en) | Application of triptonide in preparation of medicine for treating acute monocytic leukemia | |
| TWI722492B (en) | Composition containing lotus extract and its use for treating head and neck cancer | |
| WO2024060520A1 (en) | Medicament for preventing and treating tumor and use thereof | |
| CN117357543B (en) | Application of Sequiside L in breast cancer treatment | |
| TWI607751B (en) | Statin compounds for the treatment of gastric cancer | |
| CN115054610B (en) | Application of steroid compound Taccoside A in preparation of tumor immunotherapy medicine | |
| WO2019037671A1 (en) | Medicine for combined use in cancer treatment | |
| CN110856717A (en) | Tumor immunomodulator and application thereof | |
| Andriani et al. | Cytotoxic Effect of Extract Aaptos suberitoides Marine Sponge in MDA-MB 231 Triple Negative Breast Cancer Cell Line | |
| CN110772513B (en) | Medicine for treating leukemia | |
| KR102659740B1 (en) | Anti-cancer use of sea cucumber gonad extract or the compound derived from the same | |
| CN108409839A (en) | A kind of peptide inhibitor of MDM2 and p53 interactions and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |